State Street Corp decreased its holdings in shares of CareDx, Inc (NASDAQ:CDNA – Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,036,089 shares of the company’s stock after selling 71,741 shares during the quarter. State Street Corp owned 3.80% of CareDx worth $63,577,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in CDNA. Millennium Management LLC grew its holdings in shares of CareDx by 1,085.4% during the 2nd quarter. Millennium Management LLC now owns 2,140,909 shares of the company’s stock valued at $33,248,000 after purchasing an additional 1,960,308 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of CareDx by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company’s stock worth $23,492,000 after buying an additional 88,100 shares during the last quarter. Fred Alger Management LLC increased its holdings in shares of CareDx by 30.8% during the third quarter. Fred Alger Management LLC now owns 1,503,521 shares of the company’s stock worth $46,947,000 after buying an additional 353,919 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of CareDx by 78.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 696,893 shares of the company’s stock valued at $21,760,000 after acquiring an additional 306,222 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of CareDx by 802.4% in the 3rd quarter. FMR LLC now owns 625,550 shares of the company’s stock valued at $19,533,000 after acquiring an additional 556,230 shares during the last quarter.
Insider Activity at CareDx
In other news, Director Peter Maag sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 330,024 shares of the company’s stock, valued at $8,250,600. This represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.90% of the stock is owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Report on CDNA
CareDx Stock Performance
NASDAQ:CDNA opened at $20.40 on Thursday. CareDx, Inc has a 52 week low of $7.42 and a 52 week high of $34.84. The firm’s fifty day moving average is $24.09 and its 200-day moving average is $23.38. The firm has a market cap of $1.09 billion, a P/E ratio of -7.56 and a beta of 1.84.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The business had revenue of $82.88 million for the quarter, compared to analysts’ expectations of $80.04 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.43) earnings per share. As a group, sell-side analysts anticipate that CareDx, Inc will post -0.7 earnings per share for the current year.
About CareDx
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Read More
- Five stocks we like better than CareDx
- Airline Stocks – Top Airline Stocks to Buy Now
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNA – Free Report).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.